<p><strong>Bionano Genomics, Inc.</strong>（納斯達克代碼：BNGO）的股東們會很高興地看到，股價在過去一個月表現出色，上漲了 28%，並從之前的疲軟中恢復過來。但上個月的表現對過去一年 85% 的股價下跌幾乎沒有改善。</p>
<p>即使在如此大幅的價格上漲之後，Bionano Genomics 目前仍可能發出非常看漲的信號，其市銷率（&#34;P/S&#34;）為 0.7 倍，因為美國生命科學行業幾乎一半的公司市銷率超過 3.2 倍，甚至市銷率超過 7 倍的情況也並不罕見。不過，我們需要更深入地探討，以確定這種大幅降低的市銷率是否有合理的基礎。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p>查看我們對 Bionano Genomics 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/5900432-ps-multiple-vs-industry-1-dark-2/1757855588551?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/5900432-ps-multiple-vs-industry-1-dark-2/1757855588551"/></p>
<p>納斯達克 CM:BNGO 市銷率與行業比較 2025 年 9 月 14 日</p>
<h3>Bionano Genomics 最近的表現如何？</h3>
<p>Bionano Genomics 最近的表現不佳，其收入下降與其他公司相比顯得相形見絀，後者的收入平均有所增長。市銷率之所以可能較低，是因為投資者認為這種糟糕的收入表現不會有所改善。如果你仍然喜歡這家公司，你會希望情況並非如此，以便在它不受歡迎時能夠潛在地買入一些股票。</p>
<p>想知道分析師如何看待 Bionano Genomics 的未來與行業的對比嗎？在這種情況下，我們的 <strong>免費</strong> 報告是一個很好的起點。</p>
<h2>收入增長指標告訴我們關於低市銷率的什麼？</h2>
<p>你唯一會真正感到舒適的情況是，當 Bionano Genomics 的市銷率如此低迷時，公司的增長顯然落後於行業。</p>
<p>首先回顧一下，去年公司的收入增長並不令人興奮，出現了令人失望的 25% 的下降。這對其長期以來的良好表現造成了影響，因為其三年總收入增長仍然值得關注，達到了 18%。因此，我們可以首先確認，該公司在這段時間內總體上在收入增長方面做得不錯，儘管過程中有一些波折。</p>
<p>展望未來，預計未來三年每年的增長率將達到 29%，這是由兩位關注該公司的分析師估算的。這一增長率顯著高於更廣泛行業的 7.0% 年增長預測。</p>
<p>根據這些信息，我們發現 Bionano Genomics 的市銷率低於行業水平，這一點令人費解。看起來大多數投資者並不相信該公司能夠實現未來的增長預期。</p>
<h2>最終結論</h2>
<p>儘管 Bionano Genomics 的股票價格顯著上漲，但其市銷率仍然處於低迷狀態。有人認為，在某些行業中，市銷率是一個較差的價值衡量標準，但它可以是一個強有力的商業情緒指標。</p>
<p>在我們看來，Bionano Genomics 目前的市銷率顯著低於其預期的收入增長，這一增長高於其行業的其他公司。可能存在一些重大風險因素對市銷率施加下行壓力。儘管由於公司預期的高增長，股價暴跌的可能性似乎不大，但市場確實表現出一些猶豫。</p>
<p>那麼其他風險呢？每家公司都有風險，我們發現了 <strong>Bionano Genomics 的 4 個警告信號</strong>（其中 1 個有點不愉快！）你應該瞭解。</p>
<p><strong>如果你對過去盈利增長穩健的公司感興趣</strong>，你可能希望查看這份 <strong>免費</strong> 的其他強勁盈利增長和低市盈率公司的集合。</p>

BNGO

<p>Bionano Genomics, Inc.（納斯達克股票代碼：BNGO）的股價最近上漲了 28%，從過去一年顯著下跌的 85% 中恢復過來。儘管有這一漲幅，該公司的市銷率（P/S）仍然較低，為 0.7 倍，而行業平均水平為 3.2 倍。該公司的收入在去年下降了 25%，但分析師預測未來三年年均增長 29%，高於行業平均的 7%。市場似乎對 Bionano 的增長潛力持懷疑態度，導致其市銷率低迷，儘管增長預測積極</p>

<p><strong>Bionano Genomics, Inc.</strong> (NASDAQ:BNGO) shareholders would be excited to see that the share price has had a great month, posting a 28% gain and recovering from prior weakness. But the last month did very little to improve the 85% share price decline over the last year.</p>
<div class="lb-trans"><p><strong>Bionano Genomics, Inc.</strong>（納斯達克代碼：BNGO）的股東們會很高興地看到，股價在過去一個月表現出色，上漲了 28%，並從之前的疲軟中恢復過來。但上個月的表現對過去一年 85% 的股價下跌幾乎沒有改善。</p>
</div><p>Even after such a large jump in price, Bionano Genomics may still be sending very bullish signals at the moment with its price-to-sales (or &#34;P/S&#34;) ratio of 0.7x, since almost half of all companies in the Life Sciences industry in the United States have P/S ratios greater than 3.2x and even P/S higher than 7x are not unusual. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.</p>
<div class="lb-trans"><p>即使在如此大幅的價格上漲之後，Bionano Genomics 目前仍可能發出非常看漲的信號，其市銷率（&#34;P/S&#34;）為 0.7 倍，因為美國生命科學行業幾乎一半的公司市銷率超過 3.2 倍，甚至市銷率超過 7 倍的情況也並不罕見。不過，我們需要更深入地探討，以確定這種大幅降低的市銷率是否有合理的基礎。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p>Check out our latest analysis for Bionano Genomics</p>
<div class="lb-trans"><p>查看我們對 Bionano Genomics 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/5900432-ps-multiple-vs-industry-1-dark-2/1757855588551" alt="" original-src="https://images.simplywall.st/asset/chart/5900432-ps-multiple-vs-industry-1-dark-2/1757855588551"/></p>
<p>NasdaqCM:BNGO Price to Sales Ratio vs Industry September 14th 2025</p>
<div class="lb-trans"><p>納斯達克 CM:BNGO 市銷率與行業比較 2025 年 9 月 14 日</p>
</div><h3>How Has Bionano Genomics Performed Recently?</h3>
<div class="lb-trans"><h3>Bionano Genomics 最近的表現如何？</h3>
</div><p>Bionano Genomics hasn't been tracking well recently as its declining revenue compares poorly to other companies, which have seen some growth in their revenues on average. The P/S ratio is probably low because investors think this poor revenue performance isn't going to get any better. If you still like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>Bionano Genomics 最近的表現不佳，其收入下降與其他公司相比顯得相形見絀，後者的收入平均有所增長。市銷率之所以可能較低，是因為投資者認為這種糟糕的收入表現不會有所改善。如果你仍然喜歡這家公司，你會希望情況並非如此，以便在它不受歡迎時能夠潛在地買入一些股票。</p>
</div><p>Keen to find out how analysts think Bionano Genomics' future stacks up against the industry? In that case, our <strong>free</strong> report is a great place to start.</p>
<div class="lb-trans"><p>想知道分析師如何看待 Bionano Genomics 的未來與行業的對比嗎？在這種情況下，我們的 <strong>免費</strong> 報告是一個很好的起點。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The Low P/S?</h2>
<div class="lb-trans"><h2>收入增長指標告訴我們關於低市銷率的什麼？</h2>
</div><p>The only time you'd be truly comfortable seeing a P/S as depressed as Bionano Genomics' is when the company's growth is on track to lag the industry decidedly.</p>
<div class="lb-trans"><p>你唯一會真正感到舒適的情況是，當 Bionano Genomics 的市銷率如此低迷時，公司的增長顯然落後於行業。</p>
</div><p>Taking a look back first, the company's revenue growth last year wasn't something to get excited about as it posted a disappointing decline of 25%. That put a dampener on the good run it was having over the longer-term as its three-year revenue growth is still a noteworthy 18% in total. So we can start by confirming that the company has generally done a good job of growing revenue over that time, even though it had some hiccups along the way.</p>
<div class="lb-trans"><p>首先回顧一下，去年公司的收入增長並不令人興奮，出現了令人失望的 25% 的下降。這對其長期以來的良好表現造成了影響，因為其三年總收入增長仍然值得關注，達到了 18%。因此，我們可以首先確認，該公司在這段時間內總體上在收入增長方面做得不錯，儘管過程中有一些波折。</p>
</div><p>Turning to the outlook, the next three years should generate growth of 29% each year as estimated by the dual analysts watching the company. That's shaping up to be materially higher than the 7.0% per year growth forecast for the broader industry.</p>
<div class="lb-trans"><p>展望未來，預計未來三年每年的增長率將達到 29%，這是由兩位關注該公司的分析師估算的。這一增長率顯著高於更廣泛行業的 7.0% 年增長預測。</p>
</div><p>With this information, we find it odd that Bionano Genomics is trading at a P/S lower than the industry. It looks like most investors are not convinced at all that the company can achieve future growth expectations.</p>
<div class="lb-trans"><p>根據這些信息，我們發現 Bionano Genomics 的市銷率低於行業水平，這一點令人費解。看起來大多數投資者並不相信該公司能夠實現未來的增長預期。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最終結論</h2>
</div><p>Shares in Bionano Genomics have risen appreciably however, its P/S is still subdued. It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.</p>
<div class="lb-trans"><p>儘管 Bionano Genomics 的股票價格顯著上漲，但其市銷率仍然處於低迷狀態。有人認為，在某些行業中，市銷率是一個較差的價值衡量標準，但它可以是一個強有力的商業情緒指標。</p>
</div><p>To us, it seems Bionano Genomics currently trades on a significantly depressed P/S given its forecasted revenue growth is higher than the rest of its industry. There could be some major risk factors that are placing downward pressure on the P/S ratio. While the possibility of the share price plunging seems unlikely due to the high growth forecasted for the company, the market does appear to have some hesitation.</p>
<div class="lb-trans"><p>在我們看來，Bionano Genomics 目前的市銷率顯著低於其預期的收入增長，這一增長高於其行業的其他公司。可能存在一些重大風險因素對市銷率施加下行壓力。儘管由於公司預期的高增長，股價暴跌的可能性似乎不大，但市場確實表現出一些猶豫。</p>
</div><p>And what about other risks? Every company has them, and we've spotted <strong>4 warning signs for Bionano Genomics</strong> (of which 1 is a bit unpleasant!) you should know about.</p>
<div class="lb-trans"><p>那麼其他風險呢？每家公司都有風險，我們發現了 <strong>Bionano Genomics 的 4 個警告信號</strong>（其中 1 個有點不愉快！）你應該瞭解。</p>
</div><p><strong>If companies with solid past earnings growth is up your alley</strong>, you may wish to see this <strong>free</strong> collection of other companies with strong earnings growth and low P/E ratios.</p>
<div class="lb-trans"><p><strong>如果你對過去盈利增長穩健的公司感興趣</strong>，你可能希望查看這份 <strong>免費</strong> 的其他強勁盈利增長和低市盈率公司的集合。</p>
</div>

Bionano Genomics, Inc.（納斯達克代碼：BNGO）股價上漲 28% 背後缺失的一塊拼圖